Related Experiment Video
Updated: Jan 14, 2026

Ultrasonography of the Adult Male Urinary Tract for Urinary Functional Testing
Published on: August 14, 2019
Novel Stent-like Devices for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia
Roseanne Ferreira1, Mario Henrique Bitar Siqueira2, Naeem Bhojani3
1Division of Urology, Western University, London, ON, Canada.
Prostatic stents have advanced significantly for benign prostatic hyperplasia, offering improved outcomes. Modern designs provide a minimally invasive option for managing lower urinary tract symptoms.
Area of Science:
- Urology
- Biomedical Engineering
Background:
- Benign prostatic hyperplasia (BPH) causes lower urinary tract symptoms (LUTS).
- Prostatic stents were developed to manage BPH-induced LUTS.
- Early prostatic stent designs had limitations like migration and encrustation.
Purpose of the Study:
- To review the evolution of prostatic stents in managing LUTS.
- To highlight advancements in stent design and materials.
- To discuss the current role and future directions of prostatic stents.
Main Methods:
- Literature review of prostatic stent development.
- Analysis of historical and modern stent designs.
- Evaluation of clinical outcomes and complications.
Main Results:
- Significant improvements in stent durability and biocompatibility.
- Modern stents offer a minimally invasive alternative for LUTS.
- Enhanced patient outcomes with contemporary prostatic stent technology.
Conclusions:
- Prostatic stents have evolved into effective devices for LUTS management.
- Ongoing research focuses on optimizing patient selection and long-term efficacy.
- Future developments aim to reduce procedural burden and improve symptom relief.
More Related Videos
03:55Urethroplasty with Pedicled Tunica Vaginalis for the Treatment of Long-segment Anterior Urethral Stricture Caused by Lichen Sclerosus of Glans Penis
Published on: October 18, 2024
05:19A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
Published on: November 7, 2025
Related Concept Videos
Urinary Tract Calculi III: Medical Management
Anatomy of the Genitourinary System II: Bladder and Urethra
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Urinary Tract Calculi VI: Surgical Management
Mitral Stenosis III: Medical Management